Register Login

Theravance Biopharma US Inc (TBPH)

  • Event
  • July 13, 2022, 20:55 UTC

(19% Negative) THERAVANCE BIOPHARMA, INC. (TBPH) Announces Delay in units Trials for Potential Total Value ·Over $1 Due to Pandemic-Related Challenges, Regulatory Process

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 1:30 p.m.

    📋 THERAVANCE BIOPHARMA, INC. (TBPH) - Clinical Trial Update

    Filing Date: 2022-07-13

    Accepted: 2022-07-13 16:55:10

    Event Type: Clinical Trial Update

    Event Details:

    Theravance Biopharma US Inc (TBPH) Announces Clinical Trial Update Theravance Biopharma US Inc (TBPH) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: units, Pharma
    • Diseases/Conditions: Potential Total Value ·Over $1, Upfront Cash
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: Exchange
    • Updated Timeline: between 2023 and 2026

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Theravance Biopharma US Inc
    • CIK: 0001583107
    • Ticker Symbol: TBPH
    • Period End Date: 2022-07-13
    • Document Type: 8-K

Search

News categories